U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H6O3S2
Molecular Weight 142.197
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 2-MERCAPTOETHANESULFONIC ACID

SMILES

OS(=O)(=O)CCS

InChI

InChIKey=ZNEWHQLOPFWXOF-UHFFFAOYSA-N
InChI=1S/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f http://www.drugbank.ca/drugs/DB09110 https://en.wikipedia.org/wiki/Mesna

Mesna is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. No clinical drug interaction studies have been conducted with mesna. Mesna concentrates in the bladder where acrolein accumulates after administration of chemotherapy and through a Michael addition, forms a conjugate with acrolein and other urotoxic metabolites. This conjugation reaction inactivates the urotoxic compounds to harmless metabolites. The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.

CNS Activity

Originator

Approval Year

1987
114
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1037
Target ID: CHEMBL733: 4-Hydroxyifosfamide
Binding Agent
1037
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8307
MESNEX

Approved Use

Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. Mesna Injection is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. (1) Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. (1)

Launch Date

5.9944318E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
511 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, intravenous
dose: 1.2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
79 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9469350
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
110 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
201 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, intravenous
dose: 1.2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
49 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9469350
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
92 min
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9469350
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Other AEs: Headache, Hypoaesthesia...
Other AEs:
Headache (43.8%)
Hypoaesthesia (0%)
Malaise (0%)
Myalgia (0%)
Nausea (0%)
Pharyngitis (0%)
Somnolence (6.3%)
Upper respiratory infection (0%)
Vomiting (0%)
Dizziness (6.3%)
Abdominal pain (6.3%)
Coughing (0%)
Diarrhea (6.3%)
Anorexia (0%)
Flushing (12.5%)
Injection site reaction (12.5%)
Back pain (6.3%)
Dyspepsia (12.5%)
Paraesthesia (6.3%)
Renal pain (6.3%)
Rigors (12.5%)
Fatigue (0%)
Conjunctivitis (6.3%)
Arthralgia (12.5%)
Application site reaction (31.3%)
Photophobia (18.8%)
Dehydration (6.3%)
Dysuria (6.3%)
Sweating increased (6.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Other AEs: Headache, Hypoaesthesia...
Other AEs:
Headache (33.3%)
Hypoaesthesia (0%)
Malaise (8.3%)
Myalgia (0%)
Nausea (16.7%)
Pharyngitis (0%)
Somnolence (8.3%)
Upper respiratory infection (0%)
Vomiting (16.7%)
Dizziness (8.3%)
Abdominal pain (8.3%)
Coughing (0%)
Diarrhea (0%)
Anorexia (8.3%)
Flushing (0%)
Injection site reaction (0%)
Back pain (0%)
Dyspepsia (0%)
Paraesthesia (8.3%)
Renal pain (0%)
Rigors (0%)
Fatigue (8.3%)
Conjunctivitis (0%)
Arthralgia (0%)
Application site reaction (0%)
Photophobia (0%)
Dehydration (0%)
Dysuria (0%)
Sweating increased (0%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
AEs

AEs

AESignificanceDosePopulation
Anorexia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Coughing 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Fatigue 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Hypoaesthesia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Malaise 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Myalgia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Nausea 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Pharyngitis 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Upper respiratory infection 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Vomiting 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Arthralgia 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dyspepsia 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Flushing 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Injection site reaction 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Rigors 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Photophobia 18.8%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Application site reaction 31.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Headache 43.8%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Abdominal pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Back pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Conjunctivitis 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dehydration 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Diarrhea 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dizziness 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dysuria 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Paraesthesia 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Renal pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Somnolence 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Sweating increased 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Application site reaction 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Arthralgia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Back pain 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Conjunctivitis 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Coughing 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dehydration 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Diarrhea 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dyspepsia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dysuria 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Flushing 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Hypoaesthesia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Injection site reaction 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Myalgia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Pharyngitis 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Photophobia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Renal pain 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Rigors 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Sweating increased 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Upper respiratory infection 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Nausea 16.7%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Vomiting 16.7%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Headache 33.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Abdominal pain 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Anorexia 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dizziness 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Fatigue 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Malaise 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Paraesthesia 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Somnolence 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
MATE1
131

MRP2
196

P-gp
1491
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
MATE1
131
 yes
MRP2
196
 yes
P-gp
1491
 yes
PubMed

PubMed

TitleDatePubMed
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
1982
Experience with mesna in patients receiving allogeneic bone marrow transplants for poor prognostic leukaemia.
1983 Sep
Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study.
1984 Dec
[Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
1984 Sep
Encephalopathy associated with ifosphamide/mesna therapy.
1985 Feb 16
Ifosfamide, mesna, and encephalopathy.
1985 Jun 15
Ifosfamide/mesa and encephalopathy.
1985 Mar 30
Cause and prevention of mafosfamide-induced venous pain.
1986
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
1986
CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas.
1986
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
1986 Aug
Avoiding ifosfamide/mesna encephalopathy.
1986 Aug 16
Prediction of ifosfamide/mesna associated encephalopathy.
1986 Jul
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
1986 Jun
Phase II study of ifosfamide in cervical cancer.
1986 Jun
Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna.
1987
Ifosfamide/mesna encephalopathy.
1987 Apr 25
Irreversible encephalopathy with ifosfamide/mesna.
1987 Aug
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
1987 Aug
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
1987 Feb
Encephalopathy with rapid infusion ifosfamide/mesna.
1987 Feb 14
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
1987 May
Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.
1988
Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity.
1988
[Encephalopathy caused by an ifosfamide-mesna combination].
1988 Apr 2
Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin.
1988 May
Dana-Farber Cancer Institute studies in advanced sarcoma.
1990 Feb
Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation.
1991 Nov
Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO).
1992 Apr
Mesna side effects which imitate vasculitis.
1992 Aug
Response of cyclophosphamide-resistant Wegener's granulomatosis to etoposide.
1992 Aug 15
Primary tumour mutant p53 gene protein and epidermal growth factor receptor expression and doxorubicin plus ifosfamide for recurrent breast cancer.
1992 Mar
Encephalopathy in ifosfamide-treated patients.
1992 Nov
[Epileptic seizures and treatment with ifosfamide-mesna].
1994
[The prevention of hemorrhagic cystitis during the performance of bone marrow and peripheral blood stem cell transplantation in the hematologic cancer clinic].
1996
Ifosfamide encephalopathy and methylene-blue: a case report.
1996 Aug
Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
1997
Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
2003 Nov
Pelvic primitive neuroectodermal tumor associated with a cluster of small round cell tumors: case report and review of current literature.
2003 Oct
Angiogenesis inhibition by angiostatin, endostatin and TNP-470 prevents cyclophosphamide induced cystitis.
2004
Hyperbaric oxygen therapy for cyclophosphamide induced refractory hemorrhagic cystitis in a child.
2004 Aug
Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats.
2005 Aug
Doxorubicin-induced second degree and complete atrioventricular block.
2005 May
Comparison of uroprotective efficacy of mesna and amifostine in Cyclophosphamide- induced hemorrhagic cystitis in rats.
2006 Jan-Mar
Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.
2006 Nov
A 50-year-old man with burkitt lymphoma.
2008 Oct
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
2008 Sep
Increased sensitivity of glutathione S-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity.
2009 Nov
Preservation of uroplakins by 2-mercaptoethanesulfonate in cyclophosphamide-induced rat cystitis.
2011 Jan
Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity.
2013 Feb 25
Patents

Patents

05155108
3
05202324
2
07517996
3

Sample Use Guides

In Vivo Use Guide
240 mg/m2 every 4 hours (injection) or 240 mg/m2 (first point, injection) following with 480 mg/m2 (2 and 6 hours, oral).
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
2-MERCAPTOETHANESULFONIC ACID
Systematic Name English
MESNA FREE ACID
Common Name English
.BETA.-MERCAPTOETHANESULFONIC ACID
Systematic Name English
COENZYME M
Common Name English
MERCAPTOETHANESULFONIC ACID
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000180854
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
Code System Code Type Description
WIKIPEDIA
Mercaptoethanesulfonic acid
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
FDA UNII
VHD28S0H7F
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
EVMPD
SUB32737
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
DAILYMED
VHD28S0H7F
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
CHEBI
17905
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
CHEBI
58319
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
EPA CompTox
DTXSID8023264
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
ECHA (EC/EINECS)
222-167-0
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
PUBCHEM
598
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
CAS
3375-50-6
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
RXCUI
1546354
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY RxNorm
DRUG BANK
DB09110
Created by admin on Fri Dec 16 18:51:45 UTC 2022 , Edited by admin on Fri Dec 16 18:51:45 UTC 2022
PRIMARY
METABOLITE INACTIVE (PARENT)
Structure of 2,2'-DITHIODIETHANESULFONIC ACID
SALT/SOLVATE (PARENT)
Structure of MESNA
SALT/SOLVATE (PARENT)
Structure of ARGIMESNA
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966